Patient Groups & Patients
Integrity and transparency determine our collaboration with patient groups and patients
Collaborating with patient groups and patients in every part of the lifecycle of our medicines and diagnostics is core to achieving Roche’s purpose.
Sustainable partnerships with patient groups and patients is an efficient way to get valuable perspectives, knowledge and experience that influence Roche’s work across therapeutic areas—from drug development to regulatory approval, access and health policy. We collaborate with
patient groups and patients on projects ranging from real-world data (e.g. FMI and Flatiron), access to medicines, disease awareness to clinical trial design.
Different stakeholders, e.g. governments, trade associations (such as EFPIA, MedTech Europe and AdvaMed), the public and the media, call for integrity and transparency in terms of how the industry interacts with patient groups and request the disclosure of financial and in-kind
support provided by the industry. Annually, Roche publishes the names of all patient groups it works with globally, and the support provided to them, on various channels.
Roche consistently applies high standards of conduct in its collaboration with patient groups and patients. All collaborations with patient groups and patients are based on the common values of integrity, independence, respect, equity, transparency and mutual benefit.